Please consult product labels and package inserts for indications, contraindications, hazards, warnings, cautions, and information for use.  


For more information, contact:  
Bard Peripheral Vascular, Inc.  
1225 W. 3rd Street  
Tempe, AZ 85281  
USA  
Tel: 1-480-941-3510  
1-800-331-4214  
Fax: 1-480-365-7082  
1-800-440-3516  
www.bardpv.com  

For all product codes: 6F Catheter System; 0.035" Guidewire.
Comparative Stent Fatigue Survival Rates
Axial Compression & Compression / Elongation Tests

The unique, multi-step electro-polishing technology developed by BARD® reduces microscopic burrs and microcracks.

Biliary Stent Surface Finish Comparison

SEM Scanning Electron Microscopy

BARD® E·LUMINEXX® BILIARY STENT
S. M. A. R. T.® CONTROL® NITINOL STENT TRANSHEPATIC BILIARY SYSTEM
SENTINOL™ SELF-EXPANDING NITINOL BILIARY STENT SYSTEM

The displayed clinical data are taken from a number of different studies, not a head-to-head study. Each study may have varying patient profiles and protocol structures that may affect the outcome rates set forth below, and therefore is not intended to demonstrate superiority of any one product.

The LUMINEXX® Iliac Clinical Study met the success criteria for the primary endpoint; posterior probability of at least 96% that the 9-month MACE rate was ≤ 25%. MACE included peri-procedural death, TLR and stent segment restenosis and non-study stent. (Non-study stent was added post hoc to the protocol definition of MACE.)

The LUMINEXX® Iliac Clinical Study demonstrated competitive results when considering Primary Patency Rate, Anatomic Success and Mortality Rate.
Comparative Stent Fatigue Survival Rates
Axial Compression & Compression / Elongation Tests

The unique, multi-step electro-polishing technology developed by BARD® reduces microscopic burrs and microcracks.

Biliary Stent Surface Finish Comparison

SEM Scanning Electron Microscopy

The displayed clinical data are taken from a number of different studies, not a head-to-head study. Each study may have varying patient profiles and protocol structures that may affect the outcome rates set forth below, and therefore is not intended to demonstrate superiority of any one product.

The LUMINEXX® Iliac Clinical Study met the success criteria for the primary endpoint: posterior probability of at least 96% that the 9-month MACE rate was < 25%. MACE included peri-procedural death, TLR and stent segment restenosis and non-study stent. (Non-study stent was added post hoc to the protocol definition of MACE.)

The LUMINEXX® Iliac Clinical Study demonstrated competitive results when considering Primary Patency Rate, Anatomic Success and Mortality Rate.
Please consult product tables and package inserts for indications, contraindications, hazards, warnings, cautions, and information for use.

For more information, contact:
Bard Peripheral Vascular, Inc.
1225 W. 3rd Street
Tempe, AZ 85281
USA
Tel: 1-480-304-3515
1-800-331-4244
Fax: 1-480-356-7062
1-800-346-5570
www.bardpv.com

© 2008 C. R. Bard, Inc. All Rights Reserved.
◆

Designed for Endurance and Delivering VISIBLE RESULTS

For All Product Codes: 6F Catheter System; 0.035" Guidewire.